Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epigenetic Priming with Vorinostat and Pembrolizumab in ER+ Breast Cancer
NCT04190056Phase 2Terminated
- Sponsor
- University of California, San Francisco
- Start
- Mar 2021
- Primary completion
- Jun 2023
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vorinostat in breast cancer, sponsored by University of California, San Francisco. Started Mar 2021; status: terminated.
02
Drugs
vorinostat
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04190056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04190056.